Featured Research

from universities, journals, and other organizations

Stem Cell-Like Cancer Cells Resistant To Standard Therapy, Responsive To Targeted Therapy

Date:
April 30, 2008
Source:
Journal of the National Cancer Institute
Summary:
A comparison of breast cancer biopsies before and after treatment show that a subset of cells, which have stem cell-like properties, are resistant to standard chemotherapy. Tumors treated with lapatinib, which inhibits a pathway important for self-renewal, retained a smaller fraction of these tumorigenic cells after therapy.

A comparison of breast cancer biopsies before and after treatment show that a subset of cells, which have stem cell-like properties, are resistant to standard chemotherapy. Tumors treated with lapatinib, which inhibits a pathway important for self-renewal, retained a smaller fraction of these tumorigenic cells after therapy.

Several research groups have identified a subset of cells in breast tumors that have the ability to form colonies in culture and give rise to tumors in mouse models. These cells, which express CD44 protein on their surface but little or no CD24 (CD44+/CD24-/low), are frequently referred to as cancer stem cells and may be resistant to standard chemotherapeutic agents. Lapatinib, which is approved for treatment of HER2-positive breast cancer, inhibits the HER2 pathway. The drug also inhibits the epidermal growth factor receptor pathway, which may be important for stem cell proliferation.

To find out how the CD44+/CD24-/low cells respond to cytotoxic chemotherapy, Jenny Chang, M.D., from the Baylor College of Medicine in Houston and colleagues compared breast cancer biopsy samples taken from patients before and after standard chemotherapy or lapatinib therapy.

After chemotherapy, the fraction of CD44+/CD24-/low cells increased in 31 paired biopsy samples, from a mean of 4.7 percent at baseline to 13.6 percent after 12 weeks of therapy. Biopsy samples taken after chemotherapy were also more efficient at forming mammospheres, an indication of self-renewal, when grown in culture. By contrast, there was a decrease in the proportion of CD44+/CD24-/low cells in biopsies from 21 women treated with lapatinib, from 10 percent to 7.5 percent.

"Results of this study are encouraging and suggest that inhibition of key regulatory pathways responsible for self-renewal could augment the effects of conventional therapy and improve clinical outcome," the authors write.

This research was reported April 29 in the Journal of the National Cancer Institute.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Stem Cell-Like Cancer Cells Resistant To Standard Therapy, Responsive To Targeted Therapy." ScienceDaily. ScienceDaily, 30 April 2008. <www.sciencedaily.com/releases/2008/04/080429170436.htm>.
Journal of the National Cancer Institute. (2008, April 30). Stem Cell-Like Cancer Cells Resistant To Standard Therapy, Responsive To Targeted Therapy. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2008/04/080429170436.htm
Journal of the National Cancer Institute. "Stem Cell-Like Cancer Cells Resistant To Standard Therapy, Responsive To Targeted Therapy." ScienceDaily. www.sciencedaily.com/releases/2008/04/080429170436.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins